Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer

被引：1
|
作者：
Kikuchi, Eiji [1 ]
Hayakawa, Nozomi [1 ]
机构：
[1] St Marianna Univ, Dept Urol, Sch Med, Kawasaki, Kanagawa 2168511, Japan
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
10.1016/S1470-2045(20)30236-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1005 / 1006
页数：2
相关论文
共 50 条
  • [1] Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
    Apolo, Andrea B.
    Nadal, Rosa
    Tomita, Yusuke
    Davarpanah, Nicole N.
    Cordes, Lisa M.
    Steinberg, Seth M.
    Cao, Liang
    Parnes, Howard L.
    Costello, Rene
    Merino, Maria J.
    Folio, Les R.
    Lindenberg, Liza
    Raffeld, Mark
    Lin, Jeffrey
    Lee, Min-Jung
    Lee, Sunmin
    Alarcon, Sylvia V.
    Yuno, Akira
    Dawson, Nancy A.
    Allette, Kimaada
    Roy, Arpita
    De Silva, Dinuka
    Lee, Molly M.
    Sissung, Tristan M.
    Figg, William D.
    Agarwal, Piyush K.
    Wright, John J.
    Ning, Yangmin M.
    Gulley, James L.
    Dahut, William L.
    Bottaro, Donald P.
    Trepel, Jane B.
    LANCET ONCOLOGY, 2020, 21 (08): : 1099 - 1109
  • [2] Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
    Choudhury, Noura J.
    Campanile, Alexa
    Antic, Tatjana
    Yap, Kai Lee
    Fitzpatrick, Carrie A.
    Wade, James L., III
    Karrison, Theodore
    Stadler, Walter M.
    Nakamura, Yusuke
    O'Donnell, Peter H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) : 2165 - +
  • [3] Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer
    Funada, Satoshi
    Yoshioka, Takashi
    Luo, Yan
    JAMA ONCOLOGY, 2021, 7 (04) : 633 - 634
  • [4] Salvage therapy for platinum-refractory urothelial cancer: Designing new clinical trials
    Petrylak, DP
    CANCER INVESTIGATION, 2002, 20 (5-6) : 855 - 856
  • [5] Phase Ib study of avelumab and taxane based chemotherapy in platinum-refractory or ineligible metastatic urothelial cancer (AVETAX study).
    Garje, Rohan
    Packiam, Vignesh T.
    Koski, Amy
    Milhem, Mohammed M.
    O'Donnell, Michael A.
    Zakharia, Yousef
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [6] Critical treatment choices for patients with platinum-refractory urothelial carcinoma
    Lotan, Yair
    Meng, Xiaosong
    LANCET ONCOLOGY, 2020, 21 (01): : 11 - 13
  • [7] Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
    Zhang, T.
    Harrison, M.
    O'Donnell, P.
    Alva, A.
    Hahn, N.
    Appleman, L. J.
    Cetnar, J.
    Burke, J.
    Fleming, M.
    Milowsky, M.
    Mortazavi, A.
    Shore, N.
    Schmidt, E. V.
    Kresja, C.
    Chen, T.
    Bitman, B.
    Izumi, R.
    Hamdy, A.
    George, D. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study
    Parikh, Mamta
    Pan, Chong-Xian
    Beckett, Laurel A.
    Li, Yueju
    Robles, Daniel A.
    Aujla, Pawandeep K.
    Lara, Primo N., Jr.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 421 - +
  • [9] Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab
    Akashi, Yasunori
    Yamamoto, Yutaka
    Hashimoto, Mamoru
    Adomi, Shogo
    Fujita, Kazutoshi
    Kiba, Keisuke
    Minami, Takafumi
    Yoshimura, Kazuhiro
    Hirayama, Akihide
    Uemura, Hirotsugu
    CANCERS, 2023, 15 (24)
  • [10] Prognostic risk group classification for patients (pts.) with platinum-refractory metastatic urothelial cancer (UC) treated with second-line chemotherapy
    Vaughn, D. J.
    Hwang, W.
    Munier, S.
    George, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345